Based on the Lexicon Pharmaceuticals Inc stock forecast from 3 analysts, the average analyst target price for Lexicon Pharmaceuticals Inc is USD 2.55 over the next 12 months. Lexicon Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Lexicon Pharmaceuticals Inc is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, Lexicon Pharmaceuticals Inc’s stock price was USD 0.42. Lexicon Pharmaceuticals Inc’s stock price has changed by -26.57% over the past week, +24.67% over the past month and -79.67% over the last year.
No recent analyst target price found for Lexicon Pharmaceuticals Inc
No recent average analyst rating found for Lexicon Pharmaceuticals Inc
Company Overview Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease or CKD, and other cardiovascular risk factors. Its orally-delivered small molecule drug candidates under development include sotagliflozin for the treatment of hypertrophic cardiomyopathy or HCM and type 1 diabetes that is in Phase 3 clinical trial; LX9211, which has completed Phase II clinical trials for the treatment of neuropathic pain; and LX9851 for the treatment of obesity and associated cardiometabolic disorders, as well as for weight management. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas. Read Less
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company offers Sotagliflozin, an orally-delivered small molecule drug to reduce the risk of ...Read More
Frequently Asked Questions About Lexicon Pharmaceuticals Inc (LXRX) Stock
Based on ratings from 3 analysts Lexicon Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 3 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on LXRX's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for LXRX is USD 2.55 over the next 12 months. The maximum analyst target price is USD 4 while the minimum anlayst target price is USD 1.
LXRX stock's Price/Earning ratio is 16.96.
Our analysis grades LXRX stock's Price / Earning ratio at F. This means that LXRX stock's Price/Earning ratio is above 65.99999999999999% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this LXRX may be a overvalued for its sector.
The last closing price of LXRX's stock was USD 0.42.
The most recent market capitalization for LXRX is USD 0.15B.
Based on targets from 3 analysts, the average taret price for LXRX is projected at USD 2.55 over the next 12 months.
This means that LXRX's stock price may go up by +508.74% over the next 12 months.
We can't find any ETFs which contains Lexicon Pharmaceuticals Inc's stock.
As per our most recent records Lexicon Pharmaceuticals Inc has 103 Employees.
Lexicon Pharmaceuticals Inc's registered address is 2445 Technology Forest Boulevard, The Woodlands, TX, United States, 77381.
You can get more information about it from Lexicon Pharmaceuticals Inc's website at https://www.lexpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Lexicon Pharmaceuticals Inc (LXRX) Stock
Based on ratings from 3 analysts Lexicon Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 3 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on LXRX's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for LXRX is USD 2.55 over the next 12 months. The maximum analyst target price is USD 4 while the minimum anlayst target price is USD 1.
LXRX stock's Price/Earning ratio is 16.96.
Our analysis grades LXRX stock's Price / Earning ratio at F. This means that LXRX stock's Price/Earning ratio is above 65.99999999999999% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this LXRX may be a overvalued for its sector.
The last closing price of LXRX's stock was USD 0.42.
The most recent market capitalization for LXRX is USD 0.15B.
Based on targets from 3 analysts, the average taret price for LXRX is projected at USD 2.55 over the next 12 months.
This means that LXRX's stock price may go up by +508.74% over the next 12 months.
We can't find any ETFs which contains Lexicon Pharmaceuticals Inc's stock.
As per our most recent records Lexicon Pharmaceuticals Inc has 103 Employees.
Lexicon Pharmaceuticals Inc's registered address is 2445 Technology Forest Boulevard, The Woodlands, TX, United States, 77381.
You can get more information about it from Lexicon Pharmaceuticals Inc's website at https://www.lexpharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for LXRX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
